Basic Information

Common Name
B-hENPP3 MC38
Catalog Number
322250
Disease
Colon carcinoma
Organism
Mouse
Strain
C57BL/6
Aliases
B10, CD203c, NPP3, PD-IBETA, PDNP3
Tissue types
Colon
Tissue
Colon
NCBI Gene ID
Application
B-hENPP3 MC38 cells have the capability to establish tumors in vivo and can be used for efficacy studies.

Description

The mouse ENPP3 gene was replaced by human ENPP3 coding sequence in B-hENPP3 MC38 cells. Human ENPP3 is highly expressed on the surface of B-hENPP3 MC38 cells.

Targeting strategy

Gene targeting strategy for B-hENPP3 MC38 cells. The exogenous promoter and human ENPP3 coding sequence was inserted to replace part of murine exon 4 and all of exon 5. The insertion disrupts the endogenous murine ENPP3 gene, resulting in a non-functional transcript.

Protein expression analysis

ENPP3 expression analysis in B-hENPP3 MC38 cells by flow cytometry. Single cell suspensions from B-hENPP3 MC38 cultures were stained with species-specific anti-ENPP3 antibody. Human ENPP3 was detected on the surface of B-hENPP3 MC38 cells. The 2-A12 clone of B-hENPP3 MC38 cells was used for in vivo experiments.

Tumor growth curve & Body weight changes

Subcutaneous homograft tumor growth of B-hENPP3 MC38 cells. B-hENPP3 MC38 cells (1×106) were subcutaneously implanted into C57BL/6N mice (female, 10-week-old, n=6). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B)  Body weight (Mean± SEM). Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-hENPP3 MC38 cells were able to establish tumors in vivo and can be used for efficacy studies.

Protein expression analysis of tumor cells

B-hENPP3 MC38 cells were subcutaneously transplanted into C57BL/6 mice (n=6). At the end of the experiment, tumor cells were harvested and assessed for human ENPP3 expression by flow cytometry. As shown, human ENPP3 was highly expressed on the surface of tumor cells. Therefore, B-hENPP3 MC38 cells can be used for in vivo efficacy studies of novel ENPP3 therapeutics.

Back to top